CBTX

Overview

Biotech founded by Hendrik Dietz developing in vivo CAR-T products using immune-quiet single-stranded DNA delivered by targeting-ligand-decorated LNPs. CBTX is advancing a next-generation in vivo T-cell programming platform for CAR-T products using immune-quiet single-stranded DNA (not lentivirus or mRNA) delivered via targetable LNPs decorated with two targeting ligands — components that have never been tested in human patients. CBTX has locked both upstream and downstream CMC processes for its single-stranded DNA payload and is in active discussions with multiple CDMOs for tech transfer to produce clinical-grade material. (Segment 1-2 (00:00-10:00))